Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qingchang suppository versus SASP suppository for mild to moderate active ulcerative proctitis
ChiCTR1800017826Phase 4Not yet recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Sep 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in ulcerative proctitis comparing Qingchang suppository group with SASP suppository group (2 arms). Primary endpoints: Mayo score of ulcerative colitis at week 12, TCM symptom score at week 12 and 2 more. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
qingchang suppository5-aminosalicylic acid + sulphasalazine
03
Conditions
ulcerative proctitis
Beyond the preview
Go deeper on ChiCTR1800017826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017826.